FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023598910> ?p ?o ?g. }

• W3023598910 abstract "Abstract Background:Program cell death-1 (PD1) inhibitors, such as nivolumab and pembrolizumab, have shown efficacy as adjuvant treatment for cancers, including melanoma, and their frequency of use is increasing. A potential, but rare, side effect of PD1-inhibitors is acquired generalized lipodystrophy (AGL), an immune-related adverse event characterized by loss of subcutaneous adipose tissue (SAT) and insulin resistance-associated complications. AGL can result in irreversible endocrinopathies, including diabetes. Clinical Case: A 60-year-old overweight female (BMI 29.2), with no related metabolic complications or medical history of autoimmune disorders, was treated with nivolumab (240mg IV q2 weeks) for 1 year for metastatic melanoma on her right arm (staged T4bN2a) that underwent wide local resection. She completed therapy with no complications or lab abnormalities.One-month post-treatment, she noticed rapid weight loss and facial atrophy. Within 3 months, she had a 58% weight loss withsignificant loss of SAT; insulin resistance and diabetes(impaired fasting glucose 201; A1c 9.2%);hepatic steatosis diagnosed by liver biopsy; hypertriglyceridemia (5,309 mg/dL,); and undetectable leptin levels. She also developed prominent forearm muscles and leg veins. GAD antibody was negative. The loss of SAT and rapid weight loss, physical exam findings, onset of diabetes, steatosis and hypertriglyceridemia—all closely following therapy with nivolumab—led to a diagnosis of nivolumab-associated AGL. In addition to treatment for hypertriglyceridemia, the patient was placed on multiple oral and parenteral antihyperglycemic medications, including metformin, SGLT2i, GLP-1, and DPP4, but all were discontinued due to side effects. Ultimately, her A1c increased to 12.4% and she was placed on basal/bolus therapy. Discussion: AGL is associated with an increased risk of lymphoma. Metreleptin, a recombinant analogue of human leptin, is approved for treatment of metabolic complications of AGL. Some instances of lymphoma in AGL have occurred while the patient was receiving metreleptin, but data is inconclusive as to whether development of lymphoma is a side effect of metreleptin.(Brown RJ, Chan JL, Jaffe ES, et al, 2016) We believe treatment with metreleptin would have benefited our patient, but she declined due to potential side effects, including lymphoma. Nine months after nivolomuab therapy, her melanoma is in remission but she still has lipodystrophic characteristics with insulin resistant diabetes. She is being treated with pioglitazone and multiple daily insulin injections but has not achieved euglycemia despite a total daily insulin dose of 2 u/kg. Of note, injecting insulin and use of a continuous glucose monitor have been a challenge given the lack of SAT. Although AGL resulting from PD1-inhibitor therapy is rare, it is a condition for which this patient will need life-long treatment." @default.
• W3023598910 created "2020-05-13" @default.
• W3023598910 creator A5016941057 @default.
• W3023598910 creator A5036450706 @default.
• W3023598910 date "2020-04-01" @default.
• W3023598910 modified "2023-10-03" @default.
• W3023598910 title "SUN-610 Acquired Generalized Lipodystrophy: A Rare Side Effect of PD1-Inhibitor Therapy" @default.
• W3023598910 doi "https://doi.org/10.1210/jendso/bvaa046.1234" @default.
• W3023598910 hasPublicationYear "2020" @default.
• W3023598910 type Work @default.
• W3023598910 sameAs 3023598910 @default.
• W3023598910 citedByCount "0" @default.
• W3023598910 crossrefType "journal-article" @default.
• W3023598910 hasAuthorship W3023598910A5016941057 @default.
• W3023598910 hasAuthorship W3023598910A5036450706 @default.
• W3023598910 hasBestOaLocation W30235989101 @default.
• W3023598910 hasConcept C121608353 @default.
• W3023598910 hasConcept C126322002 @default.
• W3023598910 hasConcept C134018914 @default.
• W3023598910 hasConcept C141071460 @default.
• W3023598910 hasConcept C142462285 @default.
• W3023598910 hasConcept C203014093 @default.
• W3023598910 hasConcept C2776175330 @default.
• W3023598910 hasConcept C2776919658 @default.
• W3023598910 hasConcept C2777391703 @default.
• W3023598910 hasConcept C2777701055 @default.
• W3023598910 hasConcept C2778163477 @default.
• W3023598910 hasConcept C2778913445 @default.
• W3023598910 hasConcept C2779306644 @default.
• W3023598910 hasConcept C2780030458 @default.
• W3023598910 hasConcept C2780941825 @default.
• W3023598910 hasConcept C2993143319 @default.
• W3023598910 hasConcept C3013748606 @default.
• W3023598910 hasConcept C511355011 @default.
• W3023598910 hasConcept C544821477 @default.
• W3023598910 hasConcept C71924100 @default.
• W3023598910 hasConcept C90924648 @default.
• W3023598910 hasConceptScore W3023598910C121608353 @default.
• W3023598910 hasConceptScore W3023598910C126322002 @default.
• W3023598910 hasConceptScore W3023598910C134018914 @default.
• W3023598910 hasConceptScore W3023598910C141071460 @default.
• W3023598910 hasConceptScore W3023598910C142462285 @default.
• W3023598910 hasConceptScore W3023598910C203014093 @default.
• W3023598910 hasConceptScore W3023598910C2776175330 @default.
• W3023598910 hasConceptScore W3023598910C2776919658 @default.
• W3023598910 hasConceptScore W3023598910C2777391703 @default.
• W3023598910 hasConceptScore W3023598910C2777701055 @default.
• W3023598910 hasConceptScore W3023598910C2778163477 @default.
• W3023598910 hasConceptScore W3023598910C2778913445 @default.
• W3023598910 hasConceptScore W3023598910C2779306644 @default.
• W3023598910 hasConceptScore W3023598910C2780030458 @default.
• W3023598910 hasConceptScore W3023598910C2780941825 @default.
• W3023598910 hasConceptScore W3023598910C2993143319 @default.
• W3023598910 hasConceptScore W3023598910C3013748606 @default.
• W3023598910 hasConceptScore W3023598910C511355011 @default.
• W3023598910 hasConceptScore W3023598910C544821477 @default.
• W3023598910 hasConceptScore W3023598910C71924100 @default.
• W3023598910 hasConceptScore W3023598910C90924648 @default.
• W3023598910 hasLocation W30235989101 @default.
• W3023598910 hasLocation W30235989102 @default.
• W3023598910 hasOpenAccess W3023598910 @default.
• W3023598910 hasPrimaryLocation W30235989101 @default.
• W3023598910 hasRelatedWork W11605023 @default.
• W3023598910 hasRelatedWork W12315578 @default.
• W3023598910 hasRelatedWork W16315943 @default.
• W3023598910 hasRelatedWork W17716314 @default.
• W3023598910 hasRelatedWork W18464236 @default.
• W3023598910 hasRelatedWork W19488281 @default.
• W3023598910 hasRelatedWork W264794 @default.
• W3023598910 hasRelatedWork W6365324 @default.
• W3023598910 hasRelatedWork W8349140 @default.
• W3023598910 hasRelatedWork W22149354 @default.
• W3023598910 isParatext "false" @default.
• W3023598910 isRetracted "false" @default.
• W3023598910 magId "3023598910" @default.
• W3023598910 workType "article" @default.